VEGF levels in patients with glioma: a systematic review and meta-analysis
Author:
Seyedmirzaei Homa12, Shobeiri Parnian12, Turgut Mehmet34, Hanaei Sara12, Rezaei Nima125
Affiliation:
1. School of Medicine , Tehran University of Medical Sciences (TUMS), Children’s Medical Center Hospital , Dr. Qarib St. , Keshavarz Blvd , Tehran 14194 , Iran 2. Universal Scientific Education and Research Network (USERN) , Tehran , Iran 3. Department of Neurosurgery , Aydın Adnan Menderes University Faculty of Medicine , Efeler , Aydın, Turkey 4. Department of Histology and Embryology , Aydın Adnan Menderes University Health Sciences Institute , Efeler , Aydın , Turkey 5. Research Center for Immunodeficiencies, Children’s Medical Center, Tehran University of Medical Sciences (TUMS) , Tehran , Iran
Abstract
Abstract
Vascular endothelial growth factor (VEGF) has a crucial role in the angiogenesis of various tumors, including glioma. As the levels of VEGF would change in patients with glioma, we conducted the current systematic review and meta-analysis to more clearly determine the VEGF level alterations in different grades of glioma. PubMed and Scopus databases were sensitively searched for all the possible keywords addressing glioma and VEGF. Case–control and cohort studies on human subjects, which measured VEGF levels were eligible to be included in the study. Out of a total number of 3,612 studies, 22 studies were included and 12 studies entered the meta-analysis. This review revealed that serum levels of VEGF in glioma patients were 1.56 pg/dL higher compared to healthy controls (P = 0.05). Besides, immunohistochemistry (IHC) measurement of VEGF in surgical biopsies indicated significant difference in these two groups as well (P = 0.02). Yet, there was not a significant difference between patients with low-grade gliomas (World Health Organization (WHO) grades I-II, LGG) and those with high-grade gliomas (WHO grades III-IV, HGG) (P = 0.43). The results of this systematic review and meta-analysis demonstrate that VEGF levels would significantly increase in glioma, and therefore, could be potentially considered as a biomarker for this cancer.
Publisher
Walter de Gruyter GmbH
Subject
General Neuroscience
Reference41 articles.
1. Awasthi, R., Rathore, R.K., Soni, P., Sahoo, P., Awasthi, A., Husain, N., Behari, S., Singh, R.K., Pandey, C.M., and Gupta, R.K. (2012). Discriminant analysis to classify glioma grading using dynamic contrast-enhanced MRI and immunohistochemical markers. Neuroradiology 54: 205–213, https://doi.org/10.1007/s00234-011-0874-y. 2. Bache, M., Rot, S., Kessler, J., Guttler, A., Wichmann, H., Greither, T., Wach, S., Taubert, H., Soling, A., Bilkenroth, U., et al. (2015). mRNA expression levels of hypoxia-induced and stem cell-associated genes in human glioblastoma. Oncol. Rep. 33: 3155–3161, https://doi.org/10.3892/or.2015.3932. 3. Barbagallo, D., Caponnetto, A., Brex, D., Mirabella, F., Barbagallo, C., Lauretta, G., Morrone, A., Certo, F., Broggi, G., Caltabiano, R., et al. (2019). CircSMARCA5 regulates VEGFA mRNA splicing and angiogenesis in glioblastoma multiforme through the binding of SRSF1, Vol. 11. Basel: Cancers. 4. Chan, A.S., Leung, S.Y., Wong, M.P., Yuen, S.T., Cheung, N., Fan, Y.W., and Chung, L.P. (1998). Expression of vascular endothelial growth factor and its receptors in the anaplastic progression of astrocytoma, oligodendroglioma, and ependymoma. Am. J. Surg. Pathol. 22: 816–826, https://doi.org/10.1097/00000478-199807000-00004. 5. Chen, W., He, D., Li, Z., Zhang, X., Pan, D., and Chen, G. (2015). Overexpression of vascular endothelial growth factor indicates poor outcomes of glioma: a systematic review and meta-analysis. Int. J. Clin. Exp. Med. 8: 8709–8719. 26309522.
Cited by
22 articles.
订阅此论文施引文献
订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献
|
|